drugset
drugset / Trial / NCT03429803

DAY101 In Gliomas and Other Tumors

NCT03429803 ↗

Phase 1 Completed 44 enrolled Karen D. Wright MD Day One Biopharmaceuticals, Inc. · collabNational Cancer Institute (NCI) · collabPLGA Fund at Pediatric Brain Tumor Foundation · collabPacific Pediatric Neuro-Oncology Consortium · collabTeam Jack Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments. The name of the study drug involved in this study is: • Tovorafenib/DAY101 (formerly TAK-580, MLN2480)

Timeline

Start
2018-02-27
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tovorafenib Small molecule — Oral

Indications

low grade glioma